COMPARISON OF SOLIFENACIN VERSUS COMBINATION OF SOLIFENACIN AND TAMSULOSIN IN IMPROVING UNILATERAL DOUBLE-J STENT RELATED LOWER URINARY TRACT SYMPTOMS - A PROSPECTIVE RANDOMIZED CONTROL TRIAL

• Main Authors: Muhammad Tanveer Sajid, Sami Ur Rehman, Muhammad Akmal, Hussain Ahmad, Zahoor Iqbal Mirza, Arshad Mahmood
• Format: Article
• Language: English
• Published: The Army Press 2021-02-01
• Series: Pakistan Armed Forces Medical Journal
• Subjects: luts; solifenacin; ureteric stent-related symptoms; tamsulosin; ipss
• Online Access: https://pafmj.org/index.php/PAFMJ/article/view/2617

Objective: To compare Solifenacin versus solifenacin plus tamsulosin in terms of international prostate symptom score (IPSS) for lower urinary tract symptoms (LUTS) in patients with unilateral double-J (DJ) ureteric stents. Study Design: Comparative cross sectional study. Place and Duration of Study: Armed Forces Institute of Urology, Rawalpindi from Sep 2018 to Feb 2019. Methodology: A total of two hundred (n=200) patients of either gender aged 20-50 years, who underwent unilateral DJ stenting for different endourological procedures, were enrolled after satisfying inclusion/exclusion criteria and then randomly allocated to group A (Solifenacin 5mg once daily (OD) ± placebo for 2 weeks) or group B (Solifenacin 5mg OD ± Tamsulosin 0.4 mg OD for 2 weeks) respectively. Baseline (1st post-operative day) and Post 02 weeks treatment IPSS was recorded and analyzed. Results: Mean age of presentation in group A and group B was 41.11 ± 6.45 vs 39.86 ± 5.34 years with p-value 0.14. Majority of patients in both groups were male (34% female in group A while 31% in group B, difference being statistically insignificant p 0.65). Baseline IPSS in group A and group B was 10.33 ± 2.72 vs 10.46 ± 3.12 with pvalue 0.76 (statistically insignificant) while post 02 weeks treatment IPSS in group A and B was 9.20 ± 2.67 vs 7.88 ± 2.63 respectively with p-value <0.001, the difference being statistically significant. Conclusions: Current study revealed significant advantage of combination therapy (solifenacin ± tamsulosin) compared with solifenacin monotherapy in lowering LUTS based on IPSS in patients having unilateral......